Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02093546 · ClinicalTrials.gov registry record
Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 40
- Enrollment target
NCT02093546: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT02093546 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02093546 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
This trial assesses blood and tumor samples for the effect of trametinib with or without uprosertib on biomarkers in patients enrolled on trial GOG02290 with endometrial cancer that is persistent or has come back. Biomarkers found in the blood and tissue may be related to the reaction or response to the study drugs.
Interventions
- PROCEDURE Biospecimen Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-08-13 |
| Est. Completion | 2020-01-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02093546
The ClinicalTrials.gov registry entry for NCT02093546 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biospecimen Collection is the first listed.
NCT02093546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02093546 about?
NCT02093546 is a clinical study titled "Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290". This trial assesses blood and tumor samples for the effect of trametinib with or without uprosertib on biomarkers in patients enrolled on trial GOG02290 with endometrial cancer that is persistent or has come back. Biomarkers found in the blood and tissue may be related to the reaction or response to...
What is the current status of trial NCT02093546?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2004-08-13. Estimated completion is 2020-01-15.
What interventions are being tested in trial NCT02093546?
The interventions under investigation include: Biospecimen Collection (PROCEDURE).
Who is sponsoring clinical trial NCT02093546?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.